Diamyd Medical to participate in two key US diabetes events

Diamyd Medical participates in two significant events in the field of diabetes; the Critical Path Institute (C-path) Workshop: 21st Century Trials in New-Onset T1D, taking place virtually on June 17-18, and the American Diabetes Association's (ADA) 85th Scientific Sessions to be held in Chicago, US, on June 20-23.

Critical Path Institute Workshop
Diamyd Medical will participate in the C-Path workshop titled "21st Century Trials in New-Onset Type 1 Diabetes: How the use of C-peptide can accelerate the development of next-gen disease-modifying therapies for T1D," scheduled for June 17-18. This virtual workshop brings together researchers, physicians, industry leaders, patient advocates and regulators to discuss the current evidence for the use of C-peptide as an endpoint in clinical trials of new-onset Type 1 Diabetes. The goal is to reach conclusions and clarify the next steps in advancing disease-modifying therapies. C-path is a public-private non-profit organization with the mission to accelerate drug development in collaboration with regulators, industry and academia.

CEO Ulf Hannelius will represent Diamyd Medical in a panel discussion to provide the company’s perspective and experience from conducting clinical trials in Type 1 Diabetes and regulatory development.

For more information on the workshop see: https://c-path.org/21st-century-trials-in-new-onset-t1d/

ADA 2025
Diamyd Medical will participate at the ADA 2025 Scientific Sessions in Chicago, June 20-23, to showcase its work in disease-modifying therapies and precision medicine, with a focus on the pivotal Phase 3 trial  DIAGNODE-3, ongoing in the United States and Europe.

Diamyd Medical will also host a breakfast panel session in collaboration with Breakthrough T1D. Breakthrough T1D (formerly JDRF) is a leading global non-profit organization dedicated to accelerating breakthroughs in treatments for Type 1 Diabetes. 

The session is titled "Precision in Diagnosis, Power in Treatment: The Future of Type 1 Diabetes," featuring discussions on advancements and future directions in the treatment of Type 1 Diabetes.

The panel, co-moderated by Joshua Vieth, Senior Director, Research, Breakthrough T1D, and Ulf Hannelius, CEO, Diamyd Medical, includes the following leading clinicians, researchers, patient advocates and regulatory experts:

• Dr. Jason Gaglia, MD, MSc, Joslin Diabetes Center
• Dr. Emily Sims, MD, Indiana University School of Medicine
• Dr. Stephen Karpen, Senior Director, Regulatory Affairs, Breakthrough T1D
• Dr. Laura Jacobsen, MD, University of Florida
• Ms. Alecia Wesner, People With Diabetes Research Advocate & Clinical Trial Education Volunteer, Breakthrough T1D 

For more information on the ADA 2025 Scientific Sessions see: https://professional.diabetes.org/scientific-sessions

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes. Diamyd® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial with potential for an accelerated approval pathway in the US is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group – both in a largescale meta-analysis as well as in the Company’s prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

Diamyd Medical AB (publ)

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was submitted for publication, through the agency of the contact person set out above, at 15.05 CET on June 16, 2025.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Läs mer på Cision